**
In a rapid response to the latest Ebola outbreak in the Democratic Republic of the Congo (DRC), researchers are embarking on a groundbreaking clinical trial aimed at testing two potential treatments. This initiative comes just six weeks after the World Health Organization (WHO) designated the outbreak as a public health emergency. As confirmed cases soar and local communities grapple with fear and economic hardship, the success of these trials could herald a new chapter in the fight against this deadly virus.
Swift Action Amidst Crisis
The outbreak, which has already resulted in 1,792 confirmed cases and 625 fatalities as of 9 July, is attributed to the Bundibugyo strain of Ebola, for which no approved treatments or vaccines currently exist. The trial, known as the Partners programme, has begun in the Ituri region, specifically in Bunia, the provincial capital. This unprecedented speed in mobilising a clinical trial underscores the urgency of the situation as healthcare workers and families face a daunting challenge.
Neema Haba, a local mother of three, expressed the frustration felt by many in her community. “I hope these drug trials proceed quickly,” she said. “Financially, we are being driven to the brink by this outbreak and nothing is going right. We are struggling to provide for our children.” The emotional and economic toll of the outbreak is palpable, as families wrestle with the dual threats of illness and financial instability.
The Research Landscape
The Partners trial is investigating the efficacy of two drugs: remdesivir, an antiviral developed by Gilead Sciences, and MBP134, a monoclonal antibody created by Mapp Biopharmaceutical. Patients enrolled in the trial will receive either medication, a combination of both, or standard supportive care. Given their prior success in animal models against the Bundibugyo virus, researchers are hopeful that these treatments will be effective in reducing mortality rates among infected individuals.
Prof Laurens Liesenborghs from the Institute of Tropical Medicine in Antwerp is optimistic about the potential outcomes. “These two drugs actually have been proven to work against the Bundibugyo virus in animal models,” he noted. “Now we need to test it in humans. Basically, what we want to see is if they indeed can lower mortality.” Historically, Bundibugyo has a lower death rate compared to the more notorious Zaire strain, yet it remains lethal, claiming one in three lives.
Challenges on the Ground
Despite the promising start to the trial, the response to the outbreak faces significant hurdles. Healthcare workers in the Ituri region report a lack of essential supplies, including personal protective equipment and transport for deceased individuals. Additionally, community mistrust poses a serious barrier to effective treatment and containment. Ovide Maliabo, a driver for a burial team, described the dangers of their work amid local hostility: “At one point, we narrowly escaped being lynched. It’s a shame that we aren’t being financially supported.”
The situation has been exacerbated by recent protests among frontline workers demanding fair compensation for their hazardous duties. Bahati John, a team leader, lamented the lack of support, stating, “Honestly, since we started working on 15 May, with all the insults we’ve had to put up with, we haven’t seen a single penny.” This ongoing unrest could hinder the efficacy of the medical response and further strain the already fragile healthcare system.
The Path Ahead
The current trial is expected to enrol between 700 and 1,000 patients, with plans for additional sites to facilitate broader participation. WHO officials have confirmed that sufficient supplies of both remdesivir and MBP134 have been secured for approximately 1,200 patients. The commitment to include individuals of all ages, including pregnant and breastfeeding women, demonstrates a comprehensive approach to tackling the outbreak.
Prof Amanda Rojek from the University of Oxford praised the swift initiation of the trial, contrasting it with the protracted delays experienced during earlier outbreaks. “It’s just fantastic we’ve managed to get started so quickly,” she remarked, highlighting the importance of strong leadership and collaboration in the DRC.
Another trial is set to commence shortly, focusing on whether obeldesivir can prevent those exposed to the Bundibugyo strain from developing the disease. However, funding remains a pressing concern, with the Africa CDC estimating an additional $18 million is required to proceed with this initiative.
Why it Matters
The success of the Partners trial could not only save lives but also significantly enhance the DRC’s capacity to manage future outbreaks of Ebola. With the ongoing threat of the virus, effective treatments are crucial not only for the immediate health crisis but also for restoring trust within affected communities. As these trials unfold, they offer a glimmer of hope amidst a challenging landscape, underscoring the need for global solidarity and proactive healthcare initiatives in the face of infectious disease outbreaks.
